Spore.Bio raised €22M in a Series A round in Feb 2025. The company is based in Paris, France. Investors in the round: 1st Kind Ventures, Famille C Venture, LocalGlobe and 4 others. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
